We can’t show the full text here under this license. Use the link below to read it at the source.
Semaglutide versus other GLP-1 receptor agonists in patients with MASLD
Comparing semaglutide and other similar drugs in patients with fatty liver disease
AI simplified
Abstract
Semaglutide was associated with a 14% lower risk of primary composite outcomes in patients with metabolic dysfunction-associated steatotic liver disease ().
- In a study of 20,384 patients, semaglutide users had 31.8 events per 10,000 person-years compared to 36.6 events for users of other GLP-1 receptor agonists.
- Semaglutide was linked to a 32% reduction in all-cause mortality (adjusted hazard ratio 0.68).
- The risk of major adverse liver outcomes was reduced by 21% for those using semaglutide (adjusted hazard ratio 0.79).
- Benefits of semaglutide were consistent across various subgroups including age, sex, obesity status, and diabetes status.
- Comparative effectiveness showed semaglutide outperforming dulaglutide and liraglutide in terms of clinical outcomes.
AI simplified
Key numbers
0.86
Lower Risk of Composite Outcomes
for primary composite outcomes comparing semaglutide to other GLP-1RAs.
0.68
Reduction in All-Cause Mortality
for all-cause mortality comparing semaglutide to other GLP-1RAs.
0.79
Reduction in Major Adverse Liver Outcomes
for major adverse liver outcomes comparing semaglutide to other GLP-1RAs.